[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ctcl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ctcl":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100581772","phase-2-a-phase-2-study-of-ptx-100-in-patients-with-relapsedrefractory-ctcl-100581772",false,"NCT06854653","A Phase 2 Study of PTX 100 in Patients With Relapsed\u002FRefractory CTCL","An Open-Label, Phase 2 Study of PTX-100 Monotherapy in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.","Inclusion Criteria:\n\n1. Adult patient ≥18 years of age at the time of signing the informed consent.\n2. Patient is capable of giving adequate signed informed consent\n3. Have a confirmed diagnosis of CTCL with histological confirmation\n4. Patients must have greater than or equal to Stage Ib disease.\n5. Has received and failed (or intolerant of) at least 2 prior lines of prior systemic therapy for their disease.\n6. Has measurable disease defined by at least one of the following, within 28 days prior to start of study treatment: by evaluable by mSWAT or quantifiable by flow cytometry or morphology in blood or measurable by Lugano Criteria.\n7. On a stable dose of systemic corticosteroid (\\\u003C 10 mg prednisone or equivalent) are permitted. Participants on a stable dose of topical corticosteroids are permitted.\n8. Washout period- must be 2 weeks (4 weeks for monoclonal antibodies) or 5 -half-lives (whichever is longer) since any prior anti-cancer therapy.\n9. Must be human T-cell lymphotropic virus type 1 (HTLV1) negative.\n10. Has an ECOG PS of 0 to 2.\n11. Life expectancy of 3 months or greater\n12. Has adequate bone marrow function.\n13. Has adequate hepatic function.\n14. Has adequate Renal function.\n15. Has adequate coagulation function.\n16. Patients with Human Immunodeficiency virus (HIV) must be on established and stable effective anti-retroviral therapy for at least 4 weeks and have an HIV viral load of less than 400 copies\u002FmL.\n17. Male patients are eligible to participate if they agree to use a highly effective contraception during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period.\n18. Female patients are eligible to participate if they are not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    -Not a woman of childbearing potential (WOCBP).\n    * OR\n    * A WOCBP who agrees to use a contraceptive method that is highly effective (with a failure rate of \\\u003C 1% per year) or be abstinent from heterosexual intercourse as their preferred method and usual lifestyle, beginning the time of informed consent, during the treatment period and for at least 3 months after the last dose of study treatment.\n19. A WOCBP must have a negative serum pregnancy within 72 hours of the first dose of study treatment.\n20. Must be willing and able to adhere to the study as judged by the Investigator.\n\nExclusion Criteria:\n\n1. Patients with known central nervous system involvement.\n2. Patients who require the use of strong inhibitors or inducers of CYP enzymes or transporters (e.g., CYP3A4, 2D6, 2C19) or (P-gp, BCRP, OATP1B1, OATP1B3, OAT1. OAT3, OCT2, MATE1 and MATE2-K). Patients who are receiving these medications at Screening can be enrolled into the trial if they discontinue them for at least 14 days or 5 half-lives, whichever is longer, before they commence PTX-100. An alternative pharmacological treatment should be instituted by the treating clinician based on clinical judgement.\n3. Significant cardiovascular disease. A history of, or concurrent interstitial lung disease or severely impaired lung function.\n\n5\\. Active viral, bacterial, fungal infection or other serious infection requiring ongoing systemic treatment. Routine antimicrobial prophylaxis is permitted.\n\n6\\. Medical history of another malignant tumor within the past 5 years. Exceptions are patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ who have undergone curative therapy with no evidence of disease.\n\n7\\. On an immunomodulatory drug for concomitant or intercurrent conditions or who have received any of these agents within 4 weeks of baseline.\n\n8\\. Patients with active viral (any etiology) hepatitis are excluded. However, patients with serologic evidence of chronic hepatitis B virus (HBV) infection (defined by a positive hepatitis B surface antigen test and a positive anti-hepatitis core antigen antibody test) who have a viral load below the limit quantification (HBV deoxyribose nucleic acid titer \\\u003C 1000 cps\u002FmL or 200 IU\u002FmL) and are not currently on viral suppressive therapy may be eligible and should be discussed with the Medical Monitor. Patients with a history of hepatitis C virus infection who have completed curative antiviral treatment and have a viral load below the limit of quantification may be eligible and should be discussed with the Medical Monitor.\n\n9\\. A history or current evidence of any condition, laboratory abnormality or other circumstance that might confound the results of the study or interfere with patient participation for the full duration of the study.\n\n10\\. Prior allogeneic or autologous hematopoietic transplantation 11. Has a known psychiatric disorder that would interfere with compliance with the requirements of the study.\n\n12\\. Is a consumer of illicit or recreational drugs or has a recent history (within the last year) of drug or alcohol abuse or dependence that in the judgment of the Investigator, would interfere with compliance with the requirements of the study.","ALL","18 Years",{"count":19,"type":20},115,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg\u002Fm2 in patients with relapsed\u002Frefractory Cutaneous T-Cell Lymphoma (CTCL).\n\nPTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.",[26],"CTCL",[28,26,29,30,31,32,33,34],"Relapsed or refractory Cutaneous T Cell Lymphoma","PTX-100","Mycosis Fungoides","Sezary Syndrome","T Cell Lymphoma","Non-Hodgkin Lymphoma","Cutaneous Lymphoma","RECRUITING","2026-04-28",{"date":38,"type":39},"2026-04-29","ACTUAL",{"date":41,"type":39},"2025-03-28",{"date":43,"type":20},"2028-06",{"name":45,"class":46},"Prescient Therapeutics, Ltd.","INDUSTRY",15,{"id":49,"slug":4,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100552235","NCT06470451","Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL","A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Topical HyBryte™ (Hypericin Sodium) and Visible-Light Activation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)","FLASH2","Inclusion Criteria:\n\n* Patients must have a clinical diagnosis of cutaneous T-cell lymphoma (CTCL), Stage IA, Stage IB, or Stage IIA.\n* Patients with a minimum of three (3) evaluable, discrete lesions.\n* Patients willing to follow the clinical protocol and voluntarily give their written informed consent.\n* Female patients not pregnant or nursing and willing to undergo a pregnancy test within 30 days prior to treatment initiation.\n\nExclusion Criteria:\n\n* History of sun hypersensitivity and photosensitive dermatoses including porphyria, systemic lupus erythematosus, Sjögren's syndrome, xeroderma pigmentosum, polymorphous light eruptions, or radiation therapy within 30 days of enrolling.\n* History of allergy or hypersensitivity to any of the components of HyBryte.\n* A Screening ECG with a QT interval \\>470 ms (corrected for heart rate using the Fridericia's formula).\n* All women of childbearing potential (WOCBP) and males with female partners who are WOCBP not willing to use effective contraception.\n* Patients receiving topical steroids or other topical treatments (eg, nitrogen mustard) on treated lesions for CTCL within 2 weeks of enrollment.\n* Patients receiving systemic steroids, psoralen UVA radiation therapy (PUVA), narrow band UVB light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 4 weeks of enrollment.\n* Patients who have received electron beam irradiation within 3 months of enrollment.\n* Patients with a history of significant systemic immunosuppression.\n* Patients taking other investigational drugs or drugs of abuse within 30 days of entry into this study.\n* Patients whose condition is spontaneously improving.\n* Patients with tumor stage or erythrodermic CTCL (stages IIB-IV).\n* Patients with extensive skin disease (\\>30% body surface area) who would be, in the judgement of the Principal Investigator, candidates for systemic treatment.\n* Patient has any condition that, in the judgment of the PI, is likely to interfere with participation in the study.\n* Prior participation in the current study.",{"count":56,"type":20},80,[58],"PHASE3","To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch\u002Fplaque phase cutaneous T-cell lymphoma (mycosis fungoides).",[61,26,30,62],"CTCL\u002F Mycosis Fungoides","Cutaneous T Cell Lymphoma","2026-03-30",{"date":65,"type":39},"2026-04-03",{"date":67,"type":39},"2025-01-07",{"date":69,"type":20},"2026-10",{"name":71,"class":46},"Soligenix",17,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100369230","stratactx-as-a-steroid-sparing-device-100369230","NCT04087629","StrataCTX® as a Steroid Sparing Device","Post-marketing Surveillance of StrataCTX® Flexible Wound Dressing for Use as a Steroid Sparing Agent","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to sign informed consent document\n* Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel\n* Patients with a diagnosis of CTCL who have intractable pruritis\n* Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief\n* Patients on chemo\u002Fimmunotherapy with drug induced rash\n\nExclusion Criteria:\n\n* Patients currently undergoing radiotherapy\n* Patients currently receiving oral steroids\n* Patients who are unable to apply topical medications",{"count":81,"type":20},70,[83],"NA","The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy\u002Fimmunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy\u002Fimmunotherapy for solid\u002Fhematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy\u002Fimmunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.",[26],[26,87,88,89,90],"topical steroids","StrataCTX®","cutaneous","steroid sparing","2025-09-29",{"date":93,"type":39},"2025-10-02",{"date":95,"type":39},"2021-07-07",{"date":97,"type":20},"2026-08",{"name":99,"class":100},"Columbia University","OTHER",1]